BioBusiness Seminar Series: "Investing in BioMedical Start-up Companies and Negotiating a Venture Capital Deal"
The CU Technology Transfer Office and the Colorado Alliance for Bioengineering present the BioBusiness Seminar Series: "Investing in BioMedical Start-up Companies and Negotiating a Venture Capital Deal" with Timothy Mills, MD, Managing Director, Sanderling Investments and David Drake, Director of Business Development, University of Colorado Technology Transfer Office.
Friday, February 14, 2003
10:00am: Brunch Buffet and Networking
Questions? Contact Lynn.Pae@cu.edu
Prior to joining Sanderling, Dr. Mills served as the Corporate Vice President of New Business Development and Chief Scientific Officer of Target Therapeutics, a medical device company that was acquired by Boston Scientific for $1.2 billion in 1997. He also served as the Director for Prograft Medical, a Target affiliate.
Prior to joining Target in 1994, Dr. Mills served as Director of Business Development and Advanced Research & Development in the Interventional Cardiology Division of Baxter Healthcare. Dr. Mills' academic appointments include service as the Director of the Artificial Heart Program at the University of California, Irvine Medical Center and membership in the University of California, San Francisco Radiology Department.
Dr. Mills received his Ph.D. in Bioengineering from the University of California, Berkeley & San Francisco School of Medicine, his M.S. in Electrical Engineering & Computer Science from the University of California, Berkeley, and his B.S. in Electrical Engineering from the University of Colorado, Boulder.
Dave's prior experience includes numerous roles in all aspects of senior management at start-ups ranging from 5 to 50 employees. He served as chairman and CEO of HeurisTec Corporation, a software company employing technology originally developed at CU. Dave specializes in technology company creation, mergers, and acquisitions. Earlier, he held marketing and consulting positions at Procter & Gamble and McKinsey & Company.
Dave has a BA in history and Japanese from Colgate University and an MBA from the Harvard School of Business.